The BioNTech/Pfizer team presented their 2/3 phase clinical trial in the U.S. And worldwide for your COVID-19 vaccine on July 27, 2020, following the correct effects of phase 1/2 clinical trials.
It has also pre-sold up to 750 million doses of the vaccine to the governments of the USA, Japan and the UK.
The BioNTech/Pfizer team has substantial and probably unbeatable competitive and outright advantages over all its competitors.
I have a target price of around $200 for BioNTech by the end of 2020 but with FDA approval potentially in October 2020, the target price may realize earlier.
BioNTech chart source: Wikipedia.
BioNTech SE (BNTX) is a biotechnology company founded in Germany that has partnered with Pfizer (NYSE: PFE) to advertise a COVID-19 vaccine. There is no publicity or economic precedent for this pandemic or how to estimate the price of a good COVID-19 fortuitous vaccine, or how to estimate the price of a good fortuitous corporate vaccine. Following a technique to assess the progress of the progression, customers for good fortune, trading positioning and competitive advantages, I will make indicative calculations at a price based on good fortune for BioNTech shares.
BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.”
BioNTech studies in collaboration with Pfizer to expand mRN-based influenza prevention vaccines are the best for either party to start a new collaboration at COVID-19 when the opportunity arises.
The collaboration aims to drive the progression of BioNTech’s first COVID-19 MUMM vaccine program, BNT162, which is expected to enter clinical trials until the end of April 2020. »
The collaboration between BioNTech and Pfizer excludes China BioNTech had already signed a strategic alliance agreement with Fosun Pharma on March 16, 2020 for its COVID-19 vaccine.
BioNTech obtained regulatory approval from the German authority Paul-Ehrlich-Institute to begin the first clinical trial of COVID-19 vaccine applicants on April 22, 2020 and announced on 29 April 2020 that they had completed the dose for the first phase cohort. 1/2 trial of COVID-19 vaccine applicants in Germany. The power and professionalism of the BioNTech/Pfizer team are already well demonstrated at this initial level by the end of April 2020. Phase 1/2 management intensified in the United States and on May 5, 2020, BioNTech announced the dosing of first participants in the United States as a component of its global COVID-19 mVAR vaccine progression program.
BioNTech tested different iterations of its vaccine in a strategy to eventually select the best-performing iteration with regards to safety and efficacy to take forward.
Let’s simplify this mNR vaccine to assess the chances of success. View it as a custom-made vehicle designed to carry a “safe” piece of the virus used by the COVID-19 in its trunk. The vehicle is then injected into a human framework and will induce the immune formula to produce an immune reaction as if it had found COVID-19. Vaccines traditionally use an herbal virus as a vehicle or a weakened edition of the virus using COVID-19. Not using a “custom vehicle,” as I will do later, can be a challenge for other vaccine manufacturers.
BioNTech funded the advancement of its COVID-19 vaccine through debt issuance and capital raising, enabling the company to stick to a responsible non-governmental marketing strategy to governments for grants.
The vaccine resulted in higher and dose-dependent degrees of RSS-CoV-2 and degrees of IGG binding to RBD after the moment dose. The average geometric titers that neutralized SARS-CoV-2 on day 43 were between 0.7 times (1 g) and 3.2 times (50 mg) for a panel of convalescent human serums for SARS-CoV-2 infection. “
T-cell responses
In addition, the first effects of the German trial demonstrate, for the first time for candidate BNT62b1, a concomitant induction of high-level CD4 and CD8 T high-level SARS-CoV-2 RBD mobile responses.
The strength of T-cell reactions varies between subjects. There is no transparent dependence at the dose point of the T-cell reaction between 1 gy 50 g, indicating that physically powerful stimulation and expansion of T cells can be achieved at low mNS dose points. “
In general, knowledge recommends that BNT162b1 be managed safely, with a manageable tolerability profile. Local reactions and systemic occasions after injection of BNT162b1 at all doses were transient, mild to moderate, with occasional severe (grade 3) symptoms and flu-like reactions at the injection site. All adverse occasions were resolved spontaneously and controlled by undeniable measures. No serious adverse occasions (GEIs) were reported and no withdrawals were reported due to adverse vaccine-related occasions. “[My fat]
Assuming clinical success, Pfizer and BioNTech [are] on track to request a regulatory review from October 2020 and, if regulatory approval or approval is obtained, plan to supply up to one hundred million doses by the end of 2020 and approximately 1.3 billion doses until the end of 2021. “
What everyone asks about vaccine developers is: can they give birth? BioNTech in collaboration with Pfizer is convinced that they can do so. Pfizer CEO responded in an interview at CNBC on July 28 as follows:
Pfizer CEO Albert Bourla: “Our estimates are real. And, of course, it’s hard to execute, yet we revel in the execution…” ‘You’ll have to have a meticulous execution to be able to provide those results. “We, with the overall effectiveness of the vaccine, will have results, enough occasions to demonstrate a difference in statistical importance until the end of September, early October. The more effective the vaccine, the faster [statistical evidence] can come.” we’re going to cut 0 [in terms of security]. “In October, we will have enough knowledge for the FDA to make the decision to give its approval … “
On July 27, Pfizer and BioNTech presented a trial that combines stages two and 3 by recruiting a diverse population in spaces where the transmission of SARS-CoV-2 is high. You will read about the effect of the vaccine on another 30,000 people in 39 U.S. states. And Brazil, Argentina and Germany. »»
The FDA approval criteria for the COVID-19 vaccine are 50% effective and when leading Operation Warp Speed advisor asked through CNN Senior Medical Correspondent Elizabeth Cohen: “Some vaccines are 97% effective, others 60%, where do you think? are we going to fall with the COVID vaccine? Answered:
It’s very difficult to predict, from cause to effect, so we’re tracking. My non-public opinion based on my delight and the biology of this virus, I think this vaccine is going to be very effective. I wouldn’t be surprised if you’re in the 90% range,” said Moncef Slaoui, a leading advisor for Operation Warp Speed. I think the question that remains open is how long the vaccine will be effective.”
His comment is very important: “How long will the vaccine last?”
So far, it indicates that immunity is fading in 2-3 months.
CIDRAP, Center for Infectious Diseases and Policies at the University of Minnesota, reports a review in China that found that antibodies in COVID-19 patients are fading.
“The study, which involved 37 asymptomatic patients and 37 symptomatic patients, showed that more than 90% of the two teams showed a sharp drop in the degrees of immunoglobulin SARS-COV-2 expresses that they give antibodies (IgG) within 2 to 3 months of the onset of infection, .Array. »
Among the main findings, IgG grades in 93% (28/30) of the asymptomatic organization and 97% (30/31) of the symptomatic organization drastically decreased the early recovery phase (8 weeks after hospital discharge). Antibody grades decreased by 71.1% in asymptomatic patients and by 76.2% in symptomatic organization. »»